SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.
Shuqui QinJin LiAiping ZhouYanqiao ZhangXianglin YuanLiangjun ZhuBaoli QinShan ZengLin ShenYing YuanWeibo WangJun LiangXianwen ZhangFeng YePing ChenHuaizhang WangZhenyan YuLu YueYong FangJianping XiongJianwei YangYiye WanXianli YinWenling WangNong XuXiaohong WangZemin XiaoHuafang SuYing WangKangsheng GuShuiping TuZishu WangBo LiuXiaohua HuWeixian LiuXiaofeng LiPublished in: Cancer communications (London, England) (2024)